Market Overview

BMO Sees A Low-Risk Biotech Buy In Replimune

BMO Sees A Low-Risk Biotech Buy In Replimune
48 Biggest Movers From Friday
50 Biggest Movers From Yesterday

Biotech Replimune Group, Inc. (NASDAQ: REPL), which conducts research and cancer treatment studies using oncolytic viruses, picked up a sell-side bull Tuesday.

The Analyst

BMO Capital Markets analyst Do Kim initiated coverage of Replimune Group with an Outperform rating and $31 price target.

The Thesis

Replimune has developed RP1, a treatment for large injected and uninjected tumors using oncolytic viruses. BMO considers the company to be low-risk because of the treatment’s similarity to T-Vec, the only FDA-approved virus of a similar nature, Kim said in the initiation note. (See the analyst's track record here.)

“We believe RP1 can deliver on heightened expectations for oncolytic viruses, with the advent of immunotherapy, which should expose tumors to greater systemic immune activity," the analyst said.

With a stronger potency compared to T-Vec, RP1 should achieve greater benefits than those revealed in T-Vec studies, Kim said.

The study of RP1 will additionally evaluate bladder cancer, nonmelanoma skin cancer and MSI-H cancers, Kim said. Pending clinical data, the treatment could be as effective in these tumor types, Kim said, adding that the MSI-H market opportunity could replicate that of melanoma.

Since the treatment is versatile, Replimune is able to market to a variety of patients, the analyst said.

“An important characteristic of oncolytic viruses is genetic engineering, which enables tumor selective targeting and expression of biologic therapies, including antibodies, ligands and cytokines."

Price Action

Replimune shares were down 0.18 percent at $17.07 at the time of publication Tuesday.

Related Links:

The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs

Regeneron To Make $100M bluebird bio Investment In Cancer Research Collaboration

Latest Ratings for REPL

Aug 2018BMO CapitalInitiates Coverage OnOutperform
Aug 2018JP MorganInitiates Coverage OnOverweight

View More Analyst Ratings for REPL
View the Latest Analyst Ratings

Posted-In: BMO Capital Markets Do KimAnalyst Color Biotech Price Target Initiation Analyst Ratings General Best of Benzinga


Related Articles (REPL)

View Comments and Join the Discussion!

Latest Ratings

PANWBMO CapitalUpgrades240.0
UAAGoldman SachsUpgrades28.0
GPSGoldman SachsDowngrades0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Pointer Telocation's Q2 Earnings Preview

Performance Food Group's Q4 Earnings Preview